The genetic testing company 23andMe said Friday it will acquire the telehealth and pharmacy startup Lemonaid, launching an ambitious effort to remake the primary care business with personalized services driven by genetic insights.
23andMe said it will pay $400 million in cash and stock for Lemonaid, whose co-founder and CEO, Paul Johnson, will become general manager of the combined company’s consumer services business. The deal is expected to close by the end of the year.
Create a display name to comment
This name will appear with your comment
